In chronic lymphocytic leukemia, SIRT3 enables metabolic adaptation confers chemoresistance via ROS buffering272, whereas in mammary carcinoma, SIRT3 inhibits Src kinase oxidation to suppress metastatic dissemination125.Moreover, SIRT3 exerts pleiotropic control over tumor microenvironmental reprogramming and cell death pathways, including fine-tuning apoptotic execution, autophagic quality control, and ferroptotic vulnerability landscapes273-275. The gene discussed is SIRT3; the disease is breast carcinoma.